Malignant hematopoietic cell lines: In Vitro models for the study of natural killer cell leukemia-lymphoma

Leukemia

Volumn 14, Issue 5, 2000, Pages 777-782

  Drexler, H G ^a   Matsuo, Y ^b  

^a LEIBNIZ INSTITUTE DSMZ GERMAN COLLECTION OF MICROORGANISMS AND CELL CULTURES   (Germany)

^b HAYASHIBARA BIOCHEMICAL LABORATORIES INC   (Japan)

Author keywords

Cell lines; Leukemia; Lymphoma; NK cell

Indexed keywords

CD1 ANTIGEN; CD16 ANTIGEN; CD2 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD5 ANTIGEN; CD56 ANTIGEN; CD57 ANTIGEN; CD7 ANTIGEN; CD8 ANTIGEN; CELL MARKER; IMMUNOGLOBULIN HEAVY CHAIN; INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR;

ADULT; B LYMPHOCYTE; CANCER CELL CULTURE; CELL GRANULE; CHROMOSOME ABERRATION; CHROMOSOME MUTATION; EPSTEIN BARR VIRUS; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA; LYMPHOBLASTOMA; LYMPHOMA; MONOCYTE; NATURAL KILLER CELL; PRIORITY JOURNAL; RECEPTOR GENE; REVIEW; STEM CELL;

EID: 0034093625     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401778     Document Type: Review

References (55)

1. Lamy T, Loughran TP Jr. Large granular lymphocyte leukemia. Educational Program Book. European Haematology Association 1998, pp 38-43.
2. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989; 47: 187-376.
3. McKenna RW, Parkin J, Kersey JH, Gajl-Peczalska KJ, Peterson L, Brunning RD. Chronic lymphoproliferative disorder with unusual clinical, morphologic, ultrastructural and membrane surface marker characteristics. Am J Med 1977; 62: 588-595.
4. Loughran TP Jr, Kadin ME, Starkebaum G, Abkowitz JL, Clark EA, Disteche C, Lum LG, Slichter SJ. Leukemia of large granular lymphocytes: association with clonal chromosomal abnormalities and autoimmune neutropenia, thrombocytopenia, and hemolytic anemia. Ann Intern Med 1985; 102: 169-175.
5. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. J Clin Pathol 1989; 42: 567-584.
6. Loughran TP Jr. Clonal diseases of large granular lymphocytes. Blood 1993; 82: 1-14.
7. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink HK, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
8. Agnarsson BA, Loughran TP, Starkebaum G, Kadin ME. The pathology of large granular lymphocyte leukemia. Hum Pathol 1989; 20: 643-651.
9. Hercend T, Schmidt RE. Characteristics and uses of natural killer cells. Immunol Today 1988; 9: 291-293.
10. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood 1990; 76: 2421-2438.
11. Lanier LL, Spits H, Phillips JH. The developmental relationship between NK cells and T cells. Immunol Today 1992; 13: 392-395.
12. Pollack SB. Production and differentiation of NK lineage cells in bone marrow. Nat Immun 1993; 12: 177-193.
13. Spits H, Lanier LL, Phillips JH. Development of human T and natural killer cells. Blood 1995; 85: 2654-2670.
14. Pellici PG, Allavena P, Subar M, Rambaldi A, Pirelli A, Di Bello M, Barbui T, Knowles DM, Dalla-Favera R, Mantovani A. T-cell receptor (α, β, γ) gene rearrangements and expression distinguish large granular lymphocyte/natural killer cells and T-cells. Blood 1987; 70: 1500-1508.
15. Oshimi K. Lymphoproliferative disorders of natural killer cells. Int J Hematol 1996; 63: 279-290.
16. Trinchieri C. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994; 84: 4008-4027.
17. Lee SM, Suen Y, Qian J, Knoppel E, Cairo MS. The regulation and biological activity of interleukin-12. Leuk Lymphoma 1998; 29: 427-438.
18. Waldmann TA, Tagaya Y. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol 1999; 17: 19-49.
19. Fehniger TA, Shah MH, Turner MJ, Van Deusen JB, Whitman SP, Cooper MA, Suzuki K, Wechser M, Goodsaid F, Caligiuri MA. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-2: implications for the innate immune response. J Immunol 1999; 162: 4511-4520.
20. Jaffe ES. Classification of natural killer (NK) cell and NK-like T-cell malignancies. Blood 1996; 87: 1207-1210.
21. Suzuki R, Nakamura S. Malignancies of natural killer (NK) cell precursor: Myeloid/NK cell precursor acute leukemia and blastic NK cell lymphoma/leukemia. Leukemia Res 1999; 23: 615-624.
22. +, CD16 myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3. Blood 1994; 84: 244-255.
23. Wong KF, Zhang YM, Chan JKC. Cytogenetic abnormalities in natural killer cell lymphoma-leukemia - is there a consistent pattern? Leuk Lymphoma 1999; 34: 241-250.
24. Kanegane H, Yachie A, Miyawaki T, Tosato G. EBV-NK cells interactions and lymphoproliterative disorders. Leuk Lymphoma 1998; 29: 491-498.
25. Kagami Y, Nakamura S, Suzuki R, Iida S, Yatabe Y, Okada Y, Kobayashi T, Tsurumi T, Seto M, Ogura M, Taguchi O, Morishima Y. Establishment of an IL-2-dependent cell line derived from 'nasal-type' NK/T-cell lymphoma of CD2+, sCD3-, CD3∈+, CD56+ phenotype and associated with the Epstein-Barr virus. Br J Haematol 1998; 103: 669-677.
26. Yagita M, Huang CL, Umehara H, Matsuo Y, Tabata R, Miyake M, Konaka Y, Takatsuki K. A novel natural killer cell line from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia 2000; 14: 922-930.
27. Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 1994; 8: 652-658.
28. Robertson MJ, Cochran KJ, Cameron C, Le JM, Tantravahi R, Ritz J. Characterization of a cell line, NKL, derived from an aggressive human natural killer leukemia. Exp Hematol 1996; 24: 406-415.
29. Tsuchiyama J, Yoshino T, Mori M, Kondoh E, Oka T, Akagi T, Hiraki A, Nakayama H, Shibuya A, Ma YX, Kawabata T, Okada S, Harada M. Characterization of a novel human natural killer-cell line (NK-YS) established from natural killer cell lymphoma/leukemia associated with Epstein-Barr virus infection. Blood 1998; 92: 1374-1383.
30. Yodoi J, Teshigawara K, Nikaido T, Fukui K, Noma T, Honjo T, Takigawa M, Sasaki M, Minato N, Tsuclo M, Uchiyama T, Maeda M. TCGF (IL-2)-receptor inducing factor(s). I. Regulation of IL-2 receptor on a natural killer-like cell line (YT cells). J Immunol 1985; 134: 1623-1630.
31. Yoneda N, Tatsumi E, Kawano S, Teshigawara K, Oka T, Fukuda M, Yamaguchi N. Detection of Epstein-Barr virus genome in natural-killer-like cell line, YT. Leukemia 1992; 6: 136-141.
32. Drexler HG, Dirks WG, MacLeod RAF, Quentmeier H, Steube KG, Uphoff CC (eds). DSMZ Catalogue of Human and Animal Cell Lines, 7th edn. Braunschweig, Germany: 1999.
33. Asada H, Okada N, Hashimoto K, Yamanishi K, Sairenji T, Hirota S, Nomura S, Kitamura Y, Yoshikawa K. Establishment and characterization of the T-cell line, EBT-8 latently infected with Epstein-Barr virus from large granular lymphocyte leukemia. Leukemia 1994; 8: 1415-1423.
34. Hsi ED, Alkan S, Wang I, Sheldon S, Nickoloff BJ, Wrone-Smith T. Cytokine profiles and differential effect of IL-2 on two new NK lymphoma cell lines. Blood 1997; 90: 258b.
35. Tsuge I, Morishima T, Morita M, Kimura H, Kuzushima K, Matsuoka H. Characterization of Epstein-Barr virus (EBV)-infected natural killer cell proliferation in patients with severe mosquito allergy: establishment of an IL-2-dependent NK-like cell line. Clin Exp Immunol 1999; 115: 385-392.
36. Takiguchi T, Sakuma M, Kim C, Ogawa Y, Takeshita S, Masaki Y, Fukutoku M, Hirose Y, Sugai S. In vitro differentiation of 2 myeloid leukemia cell lines and the effect of anti-proliferative activity by TGF-β. Br J Haematol 1998; 102: 24.
37. Kornbluth J, Flomenberg N, Dupont B. Cell surface phenotype of a cloned line of human natural killer cells. J Immunol 1982; 129: 2831-2837.
38. Zhou J, Olsen S, Moldovan J, Fu X, Sarkar FH, Moudgil VK, Callewaert DM. Glucocorticoid regulation of natural cytotoxicity: effects of cortisol on the phenotype and function of a cloned human natural killer cell line. Cell Immunol 1997; 178: 108-116.
39. H, TCRβ, TCRγ leukemia cell line (NOI-90). Leukemia 1997; 11: 245-252.
40. Komiyama A, Kawai H, Miyagawa Y, Akabane T. Childhood lymphoblastic leukemia with natural killer activity: establishment of the leukemia cell lines retaining the activity. Blood 1982; 60: 1429-1436.
41. Komiyama A, Yamada S, Kawai H, Miyagawa Y, Akabane T. Childhood acute lymphoblastic leukemia with natural killer activity. Clinical and cellular features of three cases. Cancer 1984; 54: 1547-1553.
42. Gignac SM, Steube K, Schleithoff L, Janssen JWG, MacLeod RAF, Quentmeier H, Drexler HG. Multiparameter approach in the identification of cross-contaminated leukemia cell lines. Leuk Lymphoma 1993; 10: 359-368.
43. Drexler HG, Dirks WG, MacLeod RAF. False human hematopoietic cell lines: cross-contaminations and misinterpretations. Leukemia 1999; 13: 1601-1607.
44. + human T leukemia cell line. J Immunol 1990; 144: 4703-4711.
45. O'Connor R, Cesano A, Kreider BL, Lange B, Clark SC, Nowell PC, Finan J, Rovera G, Santoli D. Growth factor-dependent differentiation along the myeloid and lymphoid lineages in an immature acute T lymphocytic leukemia. J. Immunol 1990; 145: 3779-3787.
46. O'Connor R, Cesano A, Lange B, Finan J, Nowell PC, Clark SC, Raimondi SC, Rovera G, Santoli D. Growth factor requirements of childhood T-lymphoblastic leukemia: correlation between presence of chromosomal abnormalities and ability to grow permanently in vitro. Blood 1991; 77: 1534-1545.
47. Cesano A, O'Connor R, Lange B, Finan J, Rovera G, Santoli D. Homing and progression patterns of childhood acute lymphoblastic leukemias in severe combined immunodeficiency mice. Blood 1991; 77: 2463-2474.
48. Cesano A, O'Connor R, Nowell PC, Lange B, Clark SC, Santoli D. Establishment of a karyotypically normal cytotoxic leukemic T-cell line from a T-ALL sample engrafted in SCID mice. Blood 1993; 81: 2714-2722.
49. Kojima H, Suzukawa K, Yatabe Y, Hori M, Nagasawa T, Abe T. Establishment of a new natural killer (NK) cell line, TKS-1, from a patient with aggressive type of large granular lymphocyte (LGL) leukemia. Leukemia 1994; 8: 1999-2004.
50. Fernandez LA, Pope B, Lee C, Zayed E. Aggressive natural killer cell leukemia in an adult with establishment of an NK cell line. Blood 1986; 67: 925-930.
51. Pistoia V, Carroll AJ, Prasthofer EF, Tilden AB, Zuckerman KS, Ferrarini M, Grossi CE. Establishment of Tac-negative, interleukin-2-dependent cytotoxic cell lines from large granular lymphocytes (LGL) of patients with expanded LGL populations. J Clin Immunol 1986; 6: 457-466.
52. Drexler HG, Matsuo Y. Guidelines for the characterization and publication of human malignant hematopoietic cell lines. Leukemia 1999; 13: 835-842.
53. Drexler HG, Fombonne S, Matsuo Y, Hu ZB, Hamaguchi H, Uphoff CC. p53 alterations in human leukemia-lymphoma cell lines: In vitro artifact or prerequisite for cell immortalization? Leukemia 2000; 14: 198-206.
54. Drexler HG (ed). The Leukemia-Lymphoma Cell Lines FactsBook. Academic Press: San Diego, 2000 (in press).
55. Richards SJ, Scott CS. Human NK cells in health and disease: clinical, functional, phenotypic and DNA genotypic characteristics. Leuk Lymphoma 1992; 7: 377-400.